نتائج البحث - "Caroline Robert"

1

Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS)

المساهمون: University of Zurich

مصطلحات موضوعية: Male, 0301 basic medicine, Cancer Research, Skin Neoplasms, Health-related quality of life, Medizin, Hospitalisation rate, chemistry.chemical_compound, 0302 clinical medicine, Quality of life, Antineoplastic Combined Chemotherapy Protocols, Vemurafenib, Melanoma, Aged, 80 and over, Sulfonamides, 10177 Dermatology Clinic, Binimetinib, Middle Aged, Progression-Free Survival, humanities, Oncology, Tolerability, 030220 oncology & carcinogenesis, Female, Open label, medicine.drug, Adult, Proto-Oncogene Proteins B-raf, medicine.medical_specialty, 610 Medicine & health, BRAF(V600E−K) mutant Melanoma, Young Adult, 03 medical and health sciences, BRAF/MEK inhibitors Combination, Internal medicine, medicine, Humans, In patient, Encorafenib plus binimetinib, Aged, business.industry, Repeated measures design, medicine.disease, 030104 developmental biology, chemistry, Mutation, Quality of Life, Benzimidazoles, Carbamates, business

وصف الملف: 898_Gogas_H._et_al._Quality_of_life_in_patients_with_BRAF_mutant_melanoma_receiving_the_combination_encorafenib_plus_binimetinib_EJC_2021.pdf - application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00b598bc6b0d5210f8adf8a69fd7b47bTest
https://www.zora.uzh.ch/id/eprint/203982Test/

2

Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial

المساهمون: University of Zurich, Dummer, Reinhard

المصدر: The Lancet Oncology. 19:1315-1327

مصطلحات موضوعية: Male, 0301 basic medicine, Oncology, Skin Neoplasms, Time Factors, Medizin, Phases of clinical research, Gene mutation, chemistry.chemical_compound, 0302 clinical medicine, Antineoplastic Combined Chemotherapy Protocols, Vemurafenib, Melanoma, Aged, 80 and over, Trametinib, Sulfonamides, 10177 Dermatology Clinic, Binimetinib, Middle Aged, Progression-Free Survival, Phenotype, Tolerability, 030220 oncology & carcinogenesis, Disease Progression, Female, 2730 Oncology, medicine.drug, Adult, Proto-Oncogene Proteins B-raf, medicine.medical_specialty, 610 Medicine & health, Young Adult, 03 medical and health sciences, Internal medicine, Biomarkers, Tumor, medicine, Humans, Genetic Predisposition to Disease, Progression-free survival, Protein Kinase Inhibitors, Aged, Performance status, business.industry, 030104 developmental biology, chemistry, Mutation, Benzimidazoles, Carbamates, business

وصف الملف: 775_Dummer_R._et_al._Overall_survival_in_patients_with_BRAF-mutant_melanoma_receiving_encorafenib_plus_Lancet_Oncol._2018.pdf - application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c8bb4f4dc2694f231c2c21cb1932e261Test
https://doi.org/10.1016/s1470-2045Test(18)30497-2

3

Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF -mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial

المصدر: The Lancet Oncology. 19:603-615

مصطلحات موضوعية: Adult, Male, Proto-Oncogene Proteins B-raf, 0301 basic medicine, Oncology, medicine.medical_specialty, Skin Neoplasms, Time Factors, Phases of clinical research, Young Adult, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Biomarkers, Tumor, medicine, Humans, Molecular Targeted Therapy, Progression-free survival, Vemurafenib, Melanoma, Protein Kinase Inhibitors, Aged, Aged, 80 and over, Sulfonamides, Performance status, business.industry, MEK inhibitor, Binimetinib, Middle Aged, medicine.disease, Progression-Free Survival, 030104 developmental biology, Tolerability, chemistry, 030220 oncology & carcinogenesis, Mutation, Benzimidazoles, Female, Carbamates, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::39b9a8d731aee37b91ba57a2467a28bbTest
https://doi.org/10.1016/s1470-2045Test(18)30142-6

4

Improved overall survival in melanoma with combined dabrafenib and trametinib

المساهمون: University of Zurich, Robert, Caroline

مصطلحات موضوعية: Oncology, Male, Keratoacanthoma, Indoles, Skin Neoplasms, Medizin, Kaplan-Meier Estimate, 2700 General Medicine, chemistry.chemical_compound, Antineoplastic Combined Chemotherapy Protocols, Oximes, Vemurafenib, Melanoma, Trametinib, Aged, 80 and over, education.field_of_study, Sulfonamides, Hazard ratio, Imidazoles, 10177 Dermatology Clinic, General Medicine, Middle Aged, Intention to Treat Analysis, Female, medicine.drug, Adult, Proto-Oncogene Proteins B-raf, medicine.medical_specialty, Adolescent, Pyridones, Population, 610 Medicine & health, Pyrimidinones, Young Adult, Internal medicine, medicine, Humans, education, neoplasms, Protein Kinase Inhibitors, Aged, Cobimetinib, Mitogen-Activated Protein Kinase Kinases, business.industry, Dabrafenib, medicine.disease, Survival Analysis, Surgery, chemistry, Mutation, business

وصف الملف: Robert C et al. - N Engl J Med 2014.pdf - application/pdf; Print-Electronic; application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb174f02e29f4375b8bd8c23ddb74764Test
https://doi.org/10.5167/uzh-107163Test

5

Dramatic response to radiotherapy combined with vemurafenib. Is vemurafenib a radiosensitizer?

المؤلفون: Stéphan Vagner, Alexander M.M. Eggermont, Lise Boussemart, Yungan Tao, Laurence Vilcot, Pierre Blanchard, Caroline Robert, Brigitte Dréno, Barouyr Baroudjian, Frédéric Dhermain, Christine Mateus, Eric Deutsch, Emilie Routier

المصدر: European journal of dermatology : EJD. 24(2)

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::59d40e250153d141af1fea8d646604c0Test
https://pubmed.ncbi.nlm.nih.gov/24721778Test

6

Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): Extended follow-up of a phase 3, randomised, open-label study

المساهمون: University of Zurich, McArthur, Grant A

المصدر: The Lancet. Oncology, vol 15, iss 3

مصطلحات موضوعية: Male, Indoles, Medizin, Gastroenterology, chemistry.chemical_compound, Vemurafenib, Melanoma, Cancer, Sulfonamides, education.field_of_study, Hazard ratio, 10177 Dermatology Clinic, Binimetinib, Middle Aged, Dacarbazine, Oncology, 2730 Oncology, Female, medicine.drug, Adult, Proto-Oncogene Proteins B-raf, medicine.medical_specialty, Clinical Trials and Supportive Activities, Oncology and Carcinogenesis, Population, 610 Medicine & health, Disease-Free Survival, Clinical Research, Internal medicine, Genetics, medicine, Humans, Oncology & Carcinogenesis, education, Protein Kinase Inhibitors, Aged, Cobimetinib, Performance status, business.industry, Prevention, medicine.disease, Surgery, Good Health and Well Being, chemistry, Mutation, business, Follow-Up Studies

وصف الملف: 573_McArthur_GA_et_al._-_Lancet_Oncol_2014.pdf - application/pdf; application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::377d825d8360489bb92f735b7e5e1cb4Test
http://hdl.handle.net/11365/1081256Test

7

Vemurafenib and radiosensitization

المؤلفون: Eric Deutsch, Christine Mateus, Gorana Tomasic, Catherine Boivin, Caroline Robert, Yun Gan Tao, Emilie Routier, Joël Claveau, Lise Boussemart

المصدر: JAMA dermatology. 149(7)

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ae431471b2e37a6b631505cdcfaceea6Test
https://pubmed.ncbi.nlm.nih.gov/23699661Test

8

RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors

المؤلفون: Levi A. Garraway, Antje Sucker, Emanuele Palescandolo, Piotr Dziunycz, Damien Kee, Nyam Kamsu-Kom, Patrick A. Oberholzer, Günther F.L. Hofbauer, Grant A. McArthur, Clinton J. Chalk, Caroline Robert, Adriano Piris, Robert T. Jones, Kristin G. Ardlie, Dirk Schadendorf, Christine Roden, Laura E. MacConaill

المساهمون: University of Zurich, Garraway, L A

المصدر: Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 30(3)

وصف الملف: RAS_Mutations_Are_Associated_With_the_Development_of_Cutaneous_Squamous_Cell_Tumors_in_Patients_Treated_With_RAF_Inhibitors_JCO_2011.pdf - application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c3567cff10b5be5b331260c345ce8a46Test
https://pubmed.ncbi.nlm.nih.gov/22067405Test

تنقيح النتائج